Financial Results - Standalone (Rs. in Million)
Quarter ended September 30, 2026 (Unaudited):
- Revenue from operations: ₹4,869.91
- Other income: ₹80.92
- Total Income: ₹4,950.83
- Total Expenses: ₹3,952.18
- Profit before tax: ₹998.65
- Tax expense: ₹247.72
- Profit after tax: ₹750.93
- Other comprehensive income (net of tax): (₹1.66)
- Total comprehensive income: ₹749.27
- Basic & Diluted EPS (₹): 7.41 (Not annualised)
Quarter ended June 30, 2026 (Unaudited) for comparison:
- Profit after tax: ₹527.06
- Basic & Diluted EPS (₹): 5.20
Quarter ended September 30, 2025 (Unaudited) for comparison:
- Profit after tax: ₹731.67
- Basic & Diluted EPS (₹): 7.20
Half Year ended September 30, 2026 (Unaudited):
- Revenue from operations: ₹8,975.38
- Profit after tax: ₹1,277.99
- Basic & Diluted EPS (₹): 12.61 (Not annualised)
Half Year ended September 30, 2025 (Unaudited) for comparison:
- Profit after tax: ₹1,248.87
- Basic & Diluted EPS (₹): 12.30
Year ended March 31, 2026 (Audited) for comparison:
- Profit after tax: ₹2,500.16
- Basic & Diluted EPS (₹): 24.62
Financial Results - Consolidated (Rs. in Million)
Quarter ended September 30, 2026 (Unaudited):
- Revenue from operations: ₹5,480.23
- Profit after tax: ₹838.93
- Profit attributable to owners: ₹820.91
- Basic & Diluted EPS (₹): 8.10 (Not annualised)
Half Year ended September 30, 2026 (Unaudited):
- Revenue from operations: ₹10,180.08
- Profit after tax: ₹1,464.33
- Profit attributable to owners: ₹1,426.63
- Basic & Diluted EPS (₹): 14.07 (Not annualised)
Key Operational and Strategic Updates
1. ESOP 2025 Activity:
- During the six months ended September 30, 2026, the Nomination and Remuneration Committee granted 58,260 stock options under the ESOP 2025 scheme to eligible employees.
- The exercise price per option is determined at a discount of not more than 20% on the latest available NSE closing price preceding the grant date.
- The options have a minimum vesting period of 1 year and a maximum of 10 years, exercisable up to 2 years from each vesting date.
- During the quarter, employees exercised 2,131 stock options at an exercise price of ₹1,246 each.
2. Capacity Addition - Mumbai Hospital:
- On July 29, 2026, the company executed definitive transaction documents, including a Shareholders' Agreement, for a new children and women's hospital in Malad, Mumbai.
- This project is being developed through its wholly-owned subsidiary, Rainbow Women & Children's Hospital Private Limited (RWCHPL).
- The company diluted its stake in RWCHPL by 24% as part of this initiative.
3. Acquisition of Super Prime Medical Care LLP:
- On July 29, 2026, the company executed a Partnership Interest and Contribution Transfer Agreement (PICTA) to acquire a 64% partnership interest.
- The upfront cash consideration paid was ₹185.10 million.
- An additional contingent consideration of ₹13.30 million is payable upon successful integration, bringing the total potential consideration to ₹198.40 million.
- The acquisition was completed, and controlling interest was obtained effective August 14, 2026, upon satisfaction of closing conditions. The LLP has been consolidated from this date under Ind AS 103.
- For the period from acquisition (Aug 14, 2026) to Sept 30, 2026, the LLP contributed revenues of ₹28.66 million and a profit of ₹0.53 million.
- The share of the other partners (36%) is recorded as a non-controlling interest of ₹51.93 million as of September 30, 2026.
Segment Information
The company and the group are principally engaged in a single business segment: rendering medical and healthcare services. All business operations are concentrated in India, constituting a single geographical segment.
Balance Sheet Highlights (Standalone - Unaudited as of Sept 30, 2026)
- Total Assets: ₹27,870.10 Million (Mar 31, 2026: ₹26,483.88 Million)
- Total Equity: ₹17,399.82 Million (Mar 31, 2026: ₹16,890.57 Million)
- Paid-up Equity Share Capital: ₹1,015.66 Million (Face value ₹10 each)
Cash Flow Highlights (Standalone - H1 FY27 Unaudited)
- Net cash from operating activities: ₹1,804.84 Million
- Net cash used in investing activities: (₹524.48) Million
- Net cash used in financing activities: (₹1,268.15) Million
- Cash and cash equivalents at end of period: ₹185.01 Million
Auditor's Review
The unaudited financial results were reviewed by the statutory auditors, M/s. S.R. Batliboi & Associates LLP, who issued a limited review report. Based on their review, nothing came to their attention that causes them to believe that the statement contains any material misstatement.
Availability of Results
The results are available on the websites of BSE Limited (www.bseindia.com), the National Stock Exchange of India Limited (www.nseindia.com), and the company's website (www.rainbowhospitals.in).